DE69416859T2 - Benzolsulfonyliminderivate als inhibitoren der il-1 wirkung - Google Patents

Benzolsulfonyliminderivate als inhibitoren der il-1 wirkung

Info

Publication number
DE69416859T2
DE69416859T2 DE69416859T DE69416859T DE69416859T2 DE 69416859 T2 DE69416859 T2 DE 69416859T2 DE 69416859 T DE69416859 T DE 69416859T DE 69416859 T DE69416859 T DE 69416859T DE 69416859 T2 DE69416859 T2 DE 69416859T2
Authority
DE
Germany
Prior art keywords
pct
inhibitors
derivatives
benzolsulfonylimine
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69416859T
Other languages
English (en)
Other versions
DE69416859D1 (de
Inventor
Boyd Harrison
George Ku
Scott Meikrantz
Christopher DALTON
David Stemerick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of DE69416859D1 publication Critical patent/DE69416859D1/de
Application granted granted Critical
Publication of DE69416859T2 publication Critical patent/DE69416859T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69416859T 1993-11-29 1994-11-03 Benzolsulfonyliminderivate als inhibitoren der il-1 wirkung Expired - Fee Related DE69416859T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15901493A 1993-11-29 1993-11-29
PCT/US1994/012658 WO1995014669A1 (en) 1993-11-29 1994-11-03 Novel benzenesulfonylimine derivatives as inhibitors of il-1 action

Publications (2)

Publication Number Publication Date
DE69416859D1 DE69416859D1 (de) 1999-04-08
DE69416859T2 true DE69416859T2 (de) 1999-08-05

Family

ID=22570705

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69416859T Expired - Fee Related DE69416859T2 (de) 1993-11-29 1994-11-03 Benzolsulfonyliminderivate als inhibitoren der il-1 wirkung

Country Status (21)

Country Link
US (1) US5684017A (de)
EP (1) EP0731791B1 (de)
JP (1) JPH09506345A (de)
KR (1) KR100340375B1 (de)
CN (1) CN1044116C (de)
AT (1) ATE177083T1 (de)
AU (1) AU683114B2 (de)
CA (1) CA2175458C (de)
DE (1) DE69416859T2 (de)
DK (1) DK0731791T3 (de)
ES (1) ES2131297T3 (de)
FI (1) FI109901B (de)
GR (1) GR3029827T3 (de)
HU (1) HU219565B (de)
IL (1) IL111776A (de)
NO (1) NO306211B1 (de)
NZ (1) NZ276577A (de)
PT (1) PT731791E (de)
TW (1) TW279161B (de)
WO (1) WO1995014669A1 (de)
ZA (1) ZA949303B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
DE19705133A1 (de) * 1997-02-11 1998-08-13 Hoechst Ag Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO1999020275A1 (en) * 1997-10-17 1999-04-29 Aventis Pharmaceuticals Products Inc. Therapeutic uses of quinoline derivatives
DE19858253A1 (de) * 1998-12-17 2000-06-21 Aventis Pharma Gmbh Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
AU2002345796A1 (en) * 2001-06-26 2003-03-03 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
KR100687522B1 (ko) * 2005-05-28 2007-02-27 한국화학연구원 2,2-디메틸-3-에스테르-4-알콕시-6-알킬 아미노벤조피란 유도체를 유효성분으로 함유하는 pge2 활성에 관련된 염증질환 치료제
CN104447489B (zh) * 2014-12-29 2017-01-11 南京工业大学 3,4-二芳基马来酰亚胺衍生物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3921636A (en) * 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
CA2104297C (en) * 1991-02-27 2003-05-27 Boyd Lynn Harrison 4-sulfanimide-quinoline nmda antagonists
AU682736B2 (en) * 1993-11-29 1997-10-16 Merrell Pharmaceuticals Inc. Heterocyclic benzenesulfonylimine derivatives as inhibitors of IL-1 action

Also Published As

Publication number Publication date
CA2175458A1 (en) 1995-06-01
JPH09506345A (ja) 1997-06-24
CN1044116C (zh) 1999-07-14
WO1995014669A1 (en) 1995-06-01
EP0731791B1 (de) 1999-03-03
DE69416859D1 (de) 1999-04-08
FI962235A (fi) 1996-05-28
TW279161B (de) 1996-06-21
DK0731791T3 (da) 1999-09-27
GR3029827T3 (en) 1999-06-30
ZA949303B (en) 1995-08-07
EP0731791A1 (de) 1996-09-18
IL111776A0 (en) 1995-01-24
KR960706476A (ko) 1996-12-09
HU219565B (hu) 2001-05-28
HUT76273A (en) 1997-07-28
FI109901B (fi) 2002-10-31
CA2175458C (en) 1999-03-02
US5684017A (en) 1997-11-04
FI962235A0 (fi) 1996-05-28
ATE177083T1 (de) 1999-03-15
PT731791E (pt) 2000-11-30
IL111776A (en) 1999-06-20
CN1136311A (zh) 1996-11-20
AU1087995A (en) 1995-06-13
ES2131297T3 (es) 1999-07-16
HU9601435D0 (en) 1996-07-29
NO306211B1 (no) 1999-10-04
NZ276577A (en) 1997-11-24
NO962155L (no) 1996-05-28
NO962155D0 (no) 1996-05-28
KR100340375B1 (ko) 2002-11-13
AU683114B2 (en) 1997-10-30

Similar Documents

Publication Publication Date Title
ATE172968T1 (de) Substituierte azadioxacycloalkene und ihre verwendung als fungizide
DE69416859D1 (de) Benzolsulfonyliminderivate als inhibitoren der il-1 wirkung
DK0554247T3 (da) Neurobeskyttende indolon og beslægtede derivater
YU64092A (sh) Fluoralkoksibenzamino derivati heterocikličnih jedinjenja koja sadrže azot
FI941022A (fi) Spirosykliset piperidiinijohdannaiset
DE59406050D1 (de) Verwendung von detergensgemischen zur herstellung von toilettensteinen
DE69416324D1 (de) Heterocyclische benzolsulfonyliminderivate als inhibitoren der il-1 wirkung
FI973221A0 (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
DE69323191D1 (de) Wasserlösliche retinoide
NO972906D0 (no) 4,4-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee